Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record.

Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma: Phase II study of 32 patients

Open access
Marchi, Enrica, Alinari, Lapo, Tani, Monica, Stefoni, Vittorio, Pimpinelli, Nicola, Berti, Emilio, Pagano, Livio, Bernengo, Maria Grazia, Zaja, Francesco, Rupoli, Serena, Pileri, Stefano, Baccarani, Michele, Zinzani, Pier Luigi · 2005 · Cancer

Abstract

BACKGROUND: Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T‐cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL. METHODS: Between June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (n = 26 patients); peripheral T‐cell lymphoma, unspecified (PTCLU) with exclusive skin involvement (n = 5 patients); and Sezary syndrome (SS) (n = 1 patient) were enrolled in a 7‐institution, Phase II trial and treated with gemcitabine. This drug was given on Days 1, 8, and 15 of a 28‐day schedule at a dose of 1200 mg/m 2 intravenously over 30 minutes for a total of 6 cycles. RESULTS: Of the 32 patients studied, 7 (22%) achieved a complete response (CR) and 17 (53%) achieved a partial response (PR), whereas the remaining 8 patients showed no benefit from the treatment. Five of the CRs were confirmed histologically. The CR and PR rates were found to be the same for patients with MF and PTCLU, respectively. The median duration of CR was 10 months (range, 4–22 mos). Treatment appeared to be well tolerated; hematologic toxicity was mild and no nausea/emesis or organ toxicity was noted. CONCLUSIONS: The results of the current Phase II study demonstrate the activity of gemcitabine as a single agent in untreated CTCL patients. Further studies using gemcitabine in combination, either contemporary or sequentially, with other drugs in patients with advanced stage, untreated CTCL are needed. Cancer 2005. © 2005 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.21449

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 161

Metadata

Authors
Marchi, E., Alinari, L., Tani, M., Stefoni, V., Pimpinelli, N., Berti, E., Pagano, L., Bernengo, M. G., Zaja, F., Rupoli, S., Pileri, S., Baccarani, M., & Zinzani, P. L.
Venue
Cancer
Publisher
Wiley
Published
2005-10-07
Volume
104
Issue
11
Pages
2437-2441
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2040390735
Cited by
161
References
0
FWCI
6.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma: Phase II study of 32 patients. https://app.cochat.ai/papers/10.1002/cncr.21449
The paper
Marchi, E., Alinari, L., Tani, M., Stefoni, V., Pimpinelli, N., Berti, E., Pagano, L., Bernengo, M. G., Zaja, F., Rupoli, S., Pileri, S., Baccarani, M., & Zinzani, P. L. (2005). Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma: Phase II study of 32 patients. Cancer. https://doi.org/10.1002/cncr.21449

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.